Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Post by Diamond482on Sep 18, 2016 2:37am

139 Views

Post# 25249300

A couple of corrections to my previouis post, noithing major

My mistake .... the VYXEOS drug created by Celator is for AML, another rare type of blood cancer. However, the numbers I presented do not change much, for there are even fewer people that get AML than myelodysplastic syndromes.

[url=https://https://en.wikipedia.org/wiki/Acute_myeloid_leukemia][/url]

Epidemiology for AML

Acute myeloid leukemia is a relatively rare cancer. There are approximately 10,500 new cases each year in the United States, and the incidence rate has remained stable from 1995 through 2005. AML accounts for 1.2% of all cancer deaths in the United States.

^{Some interesting reads on the buyout and reactions.

https://seekingalpha.com/pr/16504139-jazz-pharmaceuticals-celator-pharmaceuticals-announce-agreement-jazz-pharmaceuticals-acquire

[url=https://https://seekingalpha.com/news/3186215-jazz-pharmas-deal-celator-come-today][/url]}